{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:09:18Z","timestamp":1789049358852,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220679\/Z\/20\/Z"],"award-info":[{"award-number":["220679\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011693","name":"Department for Business, Energy and Industrial Strategy, UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014095","name":"Oregon Department of Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vaccine.2024.126703","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:39:07Z","timestamp":1736613547000},"page":"126703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries"],"prefix":"10.1016","volume":"47","author":[{"given":"Adam John","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aronrag","family":"Meeyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126703_bb0005","series-title":"Zero by 30: the global strategic plan to end human deaths from dog-mediated rabies by 2030","author":"Food and Agriculture Organization of the United Nations","year":"2018"},{"key":"10.1016\/j.vaccine.2024.126703_bb0010","doi-asserted-by":"crossref","first-page":"e828","DOI":"10.1016\/S2214-109X(18)30302-4","article-title":"New global strategic plan to eliminate dog-mediated rabies by 2030","volume":"6","author":"Minghui","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.126703_bb0015","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/S0140-6736(22)02487-4","article-title":"A call to accelerate an end to human rabies deaths","volume":"400","author":"Thumbi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126703_bb0020","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2024.126703_bb0025","first-page":"1","article-title":"WHO expert consultation on rabies. Third report","author":"World Health Organization","year":"2018","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.vaccine.2024.126703_bb0030","series-title":"Rabies and rabies vaccines","first-page":"83","article-title":"Rabies vaccines, prophylactic, Peru: Massive rabies pre-exposure prophylaxis for high-risk populations","author":"Recuenco","year":"2020"},{"key":"10.1016\/j.vaccine.2024.126703_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s40475-022-00257-6","article-title":"Rabies in the tropics","volume":"9","author":"Rupprecht","year":"2022","journal-title":"Curr Trop Med Rep"},{"key":"10.1016\/j.vaccine.2024.126703_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001847","article-title":"Deaths from symptomatically identifiable furious rabies in India: a nationally representative mortality survey","volume":"6","author":"Suraweera","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0045","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0050","first-page":"38","article-title":"Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines","volume":"97","author":"Quiambao","year":"2020","journal-title":"Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0055","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1016\/j.vaccine.2009.09.027","article-title":"Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania","volume":"27","author":"Shim","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0060","first-page":"11","article-title":"A cost-effectiveness analysis of pre-exposure prophylaxis to avert rabies deaths in school-aged children in India","author":"Royal","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126703_bb0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/2395-2113.251642","article-title":"Epidemiology of dog bites in Patna: a cross sectional study","volume":"1","author":"Agarwal","year":"2015","journal-title":"Indian J Commun Family Med"},{"key":"10.1016\/j.vaccine.2024.126703_bb0070","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2024.126703_bb0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(18)30512-7","article-title":"The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study","volume":"19","author":"WHO Rabies Modeling Consortium","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0080","doi-asserted-by":"crossref","first-page":"A45","DOI":"10.1016\/j.vaccine.2018.08.086","article-title":"The need to improve access to rabies post-exposure vaccines: lessons from Tanzania","volume":"37","author":"Changalucha","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0085","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(21)00220-8","article-title":"Time to revise the strategy for Gavi funding of rabies vaccine?","volume":"397","author":"Warrell","year":"2021","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2024.126703_bb0090","doi-asserted-by":"crossref","first-page":"A166","DOI":"10.1016\/j.vaccine.2018.11.010","article-title":"Modelling to inform prophylaxis regimens to prevent human rabies","volume":"37","author":"Hampson","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0095","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 - Recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0100","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy420","article-title":"Rabies antibody response after booster immunization: a systematic review and Meta-analysis","volume":"67","author":"Langedijk","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/cid\/ciy513","article-title":"Preexposure intradermal rabies vaccination: a noninferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days","volume":"68","author":"Soentjens","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126703_bb0110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciy983","article-title":"Comparative immunogenicity and safety trial of 2 different schedules of single-visit intradermal rabies post-exposure vaccination","volume":"69","author":"Soentjens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0115","series-title":"Presonal communication: Rabies PrEP in Peru update","author":"Recuenco","year":"2024"},{"key":"10.1016\/j.vaccine.2024.126703_bb0120","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/j.vaccine.2010.02.093","article-title":"Report of the sixth AREB meeting, Manila, the Philippines, 10-12 November 2009","volume":"28","author":"Dodet","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs","volume":"119","author":"Joe","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.126703_bb0130","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2666-5247(22)00126-4","article-title":"Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-Centre, phase 1 clinical trial","volume":"3","author":"Jenkin","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2024.126703_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000339","article-title":"Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies","volume":"2","author":"Hampson","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0140","author":"The World Bank"},{"key":"10.1016\/j.vaccine.2024.126703_bb0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.vaccine.2012.11.097","article-title":"Number-needed-to-vaccinate calculations: fallacies associated with exclusion of transmission","volume":"31","author":"Tuite","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jval.2020.07.010","article-title":"Costs of immunization programs for 10 vaccines in 94 low- and middle-income countries from 2011 to 2030","volume":"24","author":"Sim","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.126703_bb0155","series-title":"A shared understanding for equitable access to vaccines","first-page":"2023","author":"Global vaccine market report","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126703_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000511","article-title":"Rabies situation in Cambodia","volume":"3","author":"Ly","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004433","article-title":"Surveillance of canine rabies in the Central African Republic: impact on human health and molecular epidemiology","volume":"10","author":"Tricou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0170","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1365-2664.2008.01468.x","article-title":"Exploring reservoir dynamics: a case study of rabies in the Serengeti ecosystem","volume":"45","author":"Lembo","year":"2008","journal-title":"J Appl Ecol"},{"key":"10.1016\/j.vaccine.2024.126703_bb0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.15585\/mmwr.mm7118a2","article-title":"Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.126703_bb0180","series-title":"Rabies: rationale for investing in the global elimination of dog-mediated human rabies","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.vaccine.2024.126703_bb0185","article-title":"Rabies control in high-burden countries: role of universal pre-exposure immunization","volume":"19","author":"Lodha","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.vaccine.2024.126703_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4269\/ajtmh.1985.34.633","article-title":"Pre-exposure rabies immunization with human diploid cell vaccine: decreased antibody responses in persons immunized in developing countries","volume":"34","author":"Bernard","year":"1985","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.126703_bb0195","first-page":"24","article-title":"Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study","author":"Jonker","year":"2017","journal-title":"J Travel Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126703_bb0200","first-page":"206","article-title":"Boostability after single-visit pre-exposure prophylaxis with rabies vaccine: a randomised controlled non-inferiority trial. Lancet Infect Dis","volume":"24","author":"Overduin","year":"2024"},{"key":"10.1016\/j.vaccine.2024.126703_bb0205","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiab034","article-title":"Long-term memory response after a single intramuscular rabies booster vaccination 10-24 years after primary immunization","volume":"226","author":"De Pijper","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0210","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.vaccine.2006.02.027","article-title":"Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity","volume":"24","author":"Suwansrinon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0215","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2024.126703_bb0220","doi-asserted-by":"crossref","first-page":"735","DOI":"10.20506\/rst.11.3.622","article-title":"Practical significance of rabies antibodies in cats and dogs","volume":"11","author":"Aubert","year":"1992","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2024.126703_bb0225","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/515267","article-title":"Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy","volume":"177","author":"Strady","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0230","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1016\/j.vaccine.2020.06.029","article-title":"Alternative abridged preventive regimens against rabies for children in high endemic countries","volume":"38","author":"Soentjens","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126703_bb0235","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/S1473-3099(22)00641-7","article-title":"Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough infections after zoonotic exposures","volume":"23","author":"Whitehouse","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0240","series-title":"Rabies and rabies vaccines","first-page":"155","article-title":"Novel rabies vaccines","author":"Ertl","year":"2020"},{"key":"10.1016\/j.vaccine.2024.126703_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2023.102612","article-title":"Single visit rabies pre-exposure prophylaxis: A literature review","volume":"54","author":"Damanet","year":"2023","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126703_bb0250","article-title":"Reassessing global historical \u211b0 estimates of canine rabies","author":"Li","year":"2024","journal-title":"bioRxiv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:23:51Z","timestamp":1740270231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24013859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"alternative-id":["S0264410X24013859"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126703","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126703"}}